Agilent heads into its fiscal third-quarter report riding a stock that has already climbed nearly 12% since its last print, roughly nine points ahead of the S&P 500, which raises a fair question: how much of the good news is already priced in? Shares sit at $148.45, just above the post-earnings high of $150.24 set during this stretch, and well clear of the 200-day moving average near $131. That is a materially tighter, higher range than the prior quarter's $108 to $125 band, suggesting the market has grown more confident in the company's trajectory rather than less.
Consensus calls for EPS of $1.48 on revenue of $1.84 billion, which would mark 8% earnings growth and nearly 6% revenue growth year over year. Management's own guidance, issued alongside the last report, calls for $1.48 to $1.50 per share on $1.83 billion to $1.85 billion in revenue, so the Street is sitting squarely inside the company's range rather than pushing beyond it. The earnings whisper of $1.51 sits modestly above consensus, and sentiment has shifted from a slightly bearish 0.4% heading into the prior quarter to 6.7% bullish now, a real but not dramatic uptick in optimism. Together these signals suggest expectations have firmed up without becoming stretched.
The last call was Agilent's strongest in recent memory, a genuine beat-and-raise built on 6.3% core growth, operating margin that jumped 130 basis points year over year to 26.4%, and pricing realization near 200 basis points, double the company's original full-year target. Management used that momentum to lift full-year EPS guidance, core growth guidance, and its margin expansion target for the second consecutive quarter, while also declaring tariff headwinds fully mitigated rather than merely being worked through. That progression matters here because repeated raises compound the burden of proof. Investors will want confirmation that the pricing gains and margin structure are holding, not just showing up in one strong quarter.
A few threads from that call deserve close attention. China revenue fell 9% last quarter, worse than expected on Lunar New Year timing, and management explicitly pushed any stimulus-driven upside out to fiscal 2027. Whether China stabilizes or deteriorates further will say a lot about whether the removal of that swing factor from guidance was the right call. Food end-market weakness, a newly introduced pressure tied to funding delays in China and India plus Middle East inflation, was cut from roughly flat to a low single digit decline, and any further slippage there would be a genuine concern given it was absent from the narrative as recently as two quarters ago. Middle East-related logistics costs and memory chip pricing were both flagged as margin pressures for the back half, with management guiding margins flat sequentially before reaccelerating into the fourth quarter. Confirming that reacceleration path, rather than a further delay, is one of the more important margin tests in this report.
On the positive side, instrument momentum has been a consistent bright spot, with nine straight quarters of book-to-bill at or above one and strong growth in diagnostics, forensics, and semiconductor-related chemical analysis markets. Newer catalysts including the Biocare acquisition and the pulled-forward launch of the 9500 ICP-MS system are not yet embedded in guidance, meaning any early commentary on their contribution could offer incremental upside rather than being a source of disappointment if it underwhelms.
The central issue for this report is whether Agilent can show that its margin and pricing gains are becoming structural rather than cyclical, even as China remains soft and new cost pressures emerge in the Middle East. A clean beat with reaffirmed or raised full-year guidance would validate the acceleration story built over the past two quarters. Anything short of that, particularly signs that food or China softness is spreading, would test a narrative that the market has already rewarded generously.